What other DCAT Member Companies are making news from DCAT Week? A roundup of the latest developments from suppliers and CDMOs/CMOs of small-molecule active pharmaceutical ingredients and packaging. 

By Jacob White, Editorial Coordinator, DCAT, jwhite@dcat.org  

Companies making the news   
Below is a roundup of recent news announcements across the bio/pharmaceutical value chain by DCAT Member Companies from DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT), which was held March 23–26, 2026.  

For a roundup of news from the DCAT Member Company Announcement Forum at DCAT Week 2026, see here.  

Chemicals/Chemical API Manufacturing 
* Aarti Pharmalabs Expanding API Mfg 
* Almac Sciences Adds New Hydrogenation Capability 
* Concept Life Sciences Investing in Early-Stage Screening and GMP Mfg 
* Esteve CDMO Expanding US Small-Molecule API Mfg Facility 
* Moehs Group Invests $18 Million to Expand API Mfg 
* SK pharmteco, Prozomix Form Biocatalysis Collaboration 
Packaging 
* ten23 health, BD in Mfg Collaboration 

Chemicals/Chemical API Manufacturing 

Aarti Pharmalabs Expanding API Mfg 
Aarti Pharmalabs, a Mumbai, Maharashtra, India-based supplier and CDMO of small-molecule active pharmaceutical ingredients (APIs), has announced manufacturing expansions backed by investments of approximately $100 million.  

The company’s greenfield project in Gujarat, India, will add capacity for small-molecule APIs and complex intermediates, with about 450 m³ manufacturing capacity expected to stabilize between FY26 and FY27. The facility will support both captive demand and the company’s growing CDMO pipeline. 

In parallel, the company is expanding at its existing site in Tarapur, India, for APIs and xanthine derivatives for improving operational scale, efficiency, and process economics. Advanced technologies, such as continuous flow chemistry and automation, are being integrated to enable higher yields, safer operations, and improved impurity control. The company is also expanding capabilities in complex chemistry platforms, including peptides, oligonucleotides, and linker-payload conjugates. Emerging technologies such as flow-based photochemistry, mechanochemistry, electrochemistry and NIR-based process analytical technology (PAT) tools are also being integrated. 

Source: Aarti Pharmalabs 

Almac Sciences Adds New Hydrogenation Capability 
Almac Sciences, a Craigavon, Northern Ireland-based CDMO of drug substances and drug products, has expanded its continuous processing platform with a new cGMP-compliant flow hydrogenation capability. The investment builds on more than eight years of dedicated development in flow chemistry, including significant experience in packed bed hydrogenation at scales exceeding 100 kg. The high-pressure system is able to support clinical and commercial programs.  

The platform complements Almac Sciences’ strengths in cryogenic organometallic chemistry, packed bed hydrogenation, and continuous processing. Together, these technologies deliver operational and environmental benefits, such as reduced solvent use, lower catalyst consumption, shorter cycle times, and greater energy efficiency. 

Source: Almac Sciences 

Concept Life Sciences Investing in Early-Stage Screening and GMP Mfg 
Concept Life Sciences, a UK-based CRO, is progressing investments across its UK facilities in 2026 to strengthen both early-stage screening and GMP manufacturing capabilities. 

The company recently completed an expansion of its screening biology infrastructure and is expanding its manufacturing capabilities. This includes the addition of new reactors to its multi-kilo facility, with completion expected in August 2026. The investment will increase the company’s overall footprint and enhance laboratory and manufacturing capacity to support the discovery and development of small molecules, peptides, including high potency APIs (HPAPIs). 

Concept Life Sciences, which is based in Discovery Park, Sandwich, UK, will scale up its operations within its kilo facility, which can handle controlled substances as well as high-potency compounds. It has been audited by the UK’s Medicines and Healthcare products Regulatory Agency and supports preclinical, clinical and commercial batch manufacturing. 

Source: Concept Life Sciences 

Esteve CDMO Expanding US Small-Molecule API Mfg Facility  
Esteve CDMO, part of Esteve, a Barcelona-based pharmaceutical company and CDMO, has commenced a $15.5-million investment to enhance production capabilities and associated space at its North American facility in Morton Grove, Illinois.  

Scheduled for completion in 2026, the work will see reactors upgraded to add powder handling and distillation tanks as well as jacket insulation and a single thermal fluid circuit to broaden operational temperature ranges to between -15°C and +140°C (5 to 284°F) and to simplify validation.  

Esteve CDMO will also implement cleanroom and ancillary equipment upgrades including a computer-based supervisory control and data acquisition (SCADA) system to monitor, control, and record manufacturing processes, and add uninterruptible power supply to safeguard quality control laboratory operations.  

Esteve added the US facility when it acquired Regis Technologies in July 2025. The site provides API services from early development to commercial manufacturing, including process R&D, analytical and stability services, and CMC support. 

Source: Esteve CDMO 

Moehs Group Invests $18 Million to Expand API Mfg 
Moehs Group, a Barcelona, Spain-based CDMO, has invested EUR 15 million ($18 million) to expand small-molecule active pharmaceutical ingredient (API) development and manufacturing. 

The investment expands the organization’s infrastructure, capacity, and technical breadth across the full small-molecule lifecycle. Moehs now operates seven production sites and two R&D centers. Capacity spans between 1 kg–2,000 kg to support preclinical, clinical, and high- and low-volume commercial supply, including for challenging processes, including high-potency and high-pressure production.  

Source: Moehs Group 

SK pharmteco, Prozomix Form Biocatalysis Collaboration 
SK pharmteco, a CDMO of small-molecule active pharmaceutical ingredients (APIs) and cell and gene therapies, has announced a collaboration with Prozomix, a UK-based company focused on enzyme diversity and biocatalyst supply. Through this collaboration, SK pharmteco will gain access to diverse specialty enzymes, enabling biocatalysis-driven API production from clinical to commercial scale. By leveraging its existing small molecule manufacturing network, SK pharmteco will integrate biocatalysis into current operations while also evaluating investments to expand enzyme screening and analytical testing capabilities.  

Source: SK pharmteco 

Packaging 

ten23 health, BD, in Mfg Collaboration 
ten23 health, a CDMO of drug products, has entered a manufacturing collaboration with Becton Dickinson (BD) to support the commercialization of BD Libertas wearable injector, a ready-to-use platform for subcutaneous delivery of large-volume biologics. The collaboration combines the BD Libertas platform (5-mL and 10-mL BD glass cartridges) with ten23 health’s process development, aseptic filling, assembly, and quality control services. ten23’s recently announced Line 0 will enable testing of cartridge compatibility, stability studies, and filling and stopper setting processes under fully representative conditions 

Source: ten23 health